Özlem Türeci
A5000036560- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- RNA Interference and Gene Delivery
- SARS-CoV-2 and COVID-19 Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- vaccines and immunoinformatics approaches
- Virus-based gene therapy research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Viral gastroenteritis research and epidemiology
- Animal Virus Infections Studies
- COVID-19 Clinical Research Studies
- Barrier Structure and Function Studies
- SARS-CoV-2 detection and testing
- Kruppel-like factors research
- Vaccine Coverage and Hesitancy
- Glycosylation and Glycoproteins Research
- Cancer Genomics and Diagnostics
- Hepatitis B Virus Studies
- RNA modifications and cancer
- Cancer Research and Treatments
- Click Chemistry and Applications
- Influenza Virus Research Studies
- Cancer-related gene regulation
BioNTech (Germany)
2012-2025
Johannes Gutenberg University Mainz
2013-2025
Helmholtz Institute Mainz
2020-2025
University Medical Center of the Johannes Gutenberg University Mainz
2010-2024
Helmholtz Institute for Translational Oncology Mainz
2020-2024
MerLion Pharma (Germany)
2013-2024
Texas Children's Hospital
2023
Pfizer (United States)
2021-2023
Johns Hopkins University
2020-2023
Stanford University
2023
BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting disease 2019 (Covid-19) have afflicted tens of millions people in a worldwide pandemic. Safe effective vaccines are needed urgently.MethodsIn an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years age or older 1:1 ratio to receive two doses, 21 days apart, either placebo BNT162b2 vaccine candidate (30 μg per dose). is lipid...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, disease 2019 (Covid-19), have spread to millions of persons worldwide. Multiple vaccine candidates are under development, but no is currently available. Interim safety immunogenicity data about candidate BNT162b1 in younger adults been reported previously from trials Germany United States.In an ongoing, placebo-controlled, observer-blinded, dose-escalation, phase 1 trial conducted States, we...
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome 2 (SARS-CoV-2)1, a pandemic. With rapidly accumulating numbers of cases and deaths reported globally2, vaccine urgently needed. Here we report available safety, tolerability immunogenicity data from an ongoing placebo-controlled, observer-blinded dose-escalation study (ClinicalTrials.gov identifier NCT04368728) among 45 healthy adults (18–55...
Ser ological analysis of re combinant cDNA ex pression libraries (SEREX) using tumor mRNA and autologous patient serum provides a powerful approach to identify immunogenic antigens. We have applied this methodology case esophageal squamous cell carcinoma identified several candidate targets. One these, NY-ESO-1, showed restricted expression in normal tissues, with high-level found only testis ovary tissues. Reverse transcription–PCR NY-ESO-1 variable proportion wide array human cancers,...
BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. highly efficacious against disease 2019 (Covid-19) and currently approved, conditionally or authorized for emergency use worldwide. At the time of initial authorization, data beyond months after vaccination were unavailable.In an ongoing, placebo-controlled, observer-blinded,...
BackgroundUntil very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age. Safe, effective are needed to protect this population, facilitate in-person learning and socialization, contribute herd immunity.MethodsIn ongoing multinational, placebo-controlled, observer-blinded trial, we randomly assigned participants a 1:1 ratio receive two injections, 21 days apart, 30 μg...
Multiple genetic events and subsequent clonal evolution drive carcinogenesis, making disease elimination with single-targeted drugs difficult. The multiplicity of gene mutations derived from heterogeneity therefore represents an ideal setting for multiepitope tumor vaccination. Here, we used next generation sequencing exome resequencing to identify 962 nonsynonymous somatic point in B16F10 murine melanoma cells, 563 those expressed genes. Potential driver occurred classical suppressor genes...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here a phase I trial adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, we synthesized mRNA real time from surgically resected PDAC tumours. After surgery, sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), cevumeran (a maximum 20 per patient) and...
Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age.A phase 1, dose-finding study and an ongoing 2-3 randomized trial being conducted to investigate the safety, immunogenicity, efficacy two doses BNT162b2 vaccine administered 21 days apart 6 months 11 age. We present results for 5-to-11-year-old children. In trial, participants were randomly assigned a 2:1 ratio receive either at dose level identified during...
Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number mutations, with 10 amino acid changes spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing either...
A one-two, CAR-T cell punch Chimeric antigen receptor (CAR)–T cells have been clinically effective in killing certain hematological malignancies, but achieving long-term patient responses for solid tumors remains a challenge. Reinhard et al. describe two-part “CARVac” strategy to overcome poor stimulation and vivo. They introduce the tight junction protein claudin 6 (CLDN6) as new target designed nanoparticulate RNA vaccine encoding chimeric directed toward CLDN6. This lipoplex promotes...
The ability to control autoreactive T cells without inducing systemic immune suppression is the major goal for treatment of autoimmune diseases. key challenge safe and efficient delivery pharmaceutically well-defined antigens in a noninflammatory context. Here, we show that nanoparticle-formulated 1 methylpseudouridine-modified messenger RNA (m1Ψ mRNA) coding disease-related autoantigens results antigen presentation on splenic CD11c+ antigen-presenting absence costimulatory signals. In...
Tumor models are critical for our understanding of cancer and the development therapeutics. Here, we present an integrated map genome, transcriptome immunome epithelial mouse tumor, CT26 colon carcinoma cell line.We found that Kras is homozygously mutated at p.G12D, Apc Tp53 not mutated, Cdkn2a deleted. Proliferation stem-cell markers, including Top2a, Birc5 (Survivin), Cldn6 Mki67, highly expressed while differentiation top-crypt markers Muc2, Ms4a8a (MS4A8B) Epcam not. Myc, Trp53 (tp53),...
The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 reference strain), Beta (B.1.351), Delta (B.1.617.2), or pseudoviruses with sera 51 participants who received two three doses messenger RNA (mRNA)-based COVID-19 vaccine BNT162b2. After doses,...